<code id='3FD7768976'></code><style id='3FD7768976'></style>
    • <acronym id='3FD7768976'></acronym>
      <center id='3FD7768976'><center id='3FD7768976'><tfoot id='3FD7768976'></tfoot></center><abbr id='3FD7768976'><dir id='3FD7768976'><tfoot id='3FD7768976'></tfoot><noframes id='3FD7768976'>

    • <optgroup id='3FD7768976'><strike id='3FD7768976'><sup id='3FD7768976'></sup></strike><code id='3FD7768976'></code></optgroup>
        1. <b id='3FD7768976'><label id='3FD7768976'><select id='3FD7768976'><dt id='3FD7768976'><span id='3FD7768976'></span></dt></select></label></b><u id='3FD7768976'></u>
          <i id='3FD7768976'><strike id='3FD7768976'><tt id='3FD7768976'><pre id='3FD7768976'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:58712
          Scanned cerebellum of a mouse brain, affected by Niemann-Pick Type C, shown in pink and teal — biotech coverage from STAT
          The cerebellum of a mouse brain affected by Niemann-Pick Type C. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

          About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo drug, probing its effects on people with balance disorders, when she thought of another, very sick group of patients. 

          A graduate student and medical resident at the German Center for Vertigo and Balance Disorders, in Munich, Bremova-Ertl often saw patients with Niemann-Pick Type C, a rare, genetic disease that slowly kills neurons. 

          advertisement

          NPC has a range of manifestations. When symptoms appear in early childhood, it is often fatal before adulthood. When it manifests  later, it can be milder. But it’s always degenerative and leads to a cluster of challenges: cognitive decline, difficulty with speech and swallowing, enlarged liver, low muscle tone, and, notably, difficulty with balance and muscle control. Researchers and a fervent group of parents were working to develop medicines, but little had yet worked. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          FDA approves potent Eli Lilly obesity drug, Zepbound
          FDA approves potent Eli Lilly obesity drug, Zepbound

          DarronCummings/APEliLilly’sblockbusterdrugtirzepatide,soldasMounjarofortype2diabetes,hasbeenclearedt

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Sanofi seeks simpler, safer CRISPR sickle cell cure

          RubyWallauforSTATSanofiwilllicenseanewCRISPRenzymefromthestartupScribeTherapeuticsinabidtobethefirst